Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53.

Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, Wardell CP, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Sawyer JR, Morgan GJ, Walker BA.

Oncotarget. 2019 Jan 22;10(7):732-737. doi: 10.18632/oncotarget.26589. eCollection 2019 Jan 22.

2.

Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.

Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A.

Transpl Infect Dis. 2019 Apr;21(2):e13052. doi: 10.1111/tid.13052. Epub 2019 Feb 15.

PMID:
30689291
3.

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0329-0. [Epub ahead of print]

PMID:
30573775
4.

A case report of delayed cortical infarction adjacent to sulcal clots after traumatic subarachnoid hemorrhage in the absence of proximal vasospasm.

Schinke C, Horst V, Schlemm L, Wawra M, Scheel M, Hartings JA, Dreier JP.

BMC Neurol. 2018 Dec 18;18(1):210. doi: 10.1186/s12883-018-1217-y.

5.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
6.

Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S.

Br J Haematol. 2019 Feb;184(4):578-593. doi: 10.1111/bjh.15669. Epub 2018 Nov 8.

PMID:
30408155
7.

Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls.

Schinke C, Hesse S, Rullmann M, Becker GA, Luthardt J, Zientek F, Patt M, Stoppe M, Schmidt E, Meyer K, Meyer PM, Orthgieß J, Blüher M, Kratzsch J, Ding YS, Then Bergh F, Sabri O.

Stress. 2019 Jan;22(1):93-102. doi: 10.1080/10253890.2018.1511698. Epub 2018 Oct 29.

PMID:
30369292
8.

FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.

Atrash S, Dua I, Buros AF, Van Rhee F, Suva LJ, Thanendrarajan S, Schinke C, Davies F, Morgan G, Zangari M.

Bone. 2019 Apr;121:134-138. doi: 10.1016/j.bone.2018.09.013. Epub 2018 Sep 19.

PMID:
30244157
9.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N.

Blood. 2018 Jul 5;132(1):59-66. doi: 10.1182/blood-2018-04-842880. Epub 2018 May 21.

PMID:
29784643
10.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23.

11.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ.

Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22.

12.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.

Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ.

Clin Cancer Res. 2018 Jun 15;24(12):2913-2919. doi: 10.1158/1078-0432.CCR-17-2627. Epub 2018 Mar 21.

PMID:
29563136
13.

Cardiovascular complications of multiple myeloma in the elderly.

Mathur P, Thanendrarajan S, Paydak H, Vallurupalli S, Jambhekar K, Bhatti S, Schinke CD, Davies FE, Mehta JL.

Expert Rev Cardiovasc Ther. 2017 Dec;15(12):933-943. doi: 10.1080/14779072.2017.1409114. Epub 2017 Nov 27. Review.

PMID:
29164945
14.

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant.

Mathur P, Hollowoa B, Lala N, Thanendrarajan S, Matin A, Kothari A, Schinke C.

Hematol Rep. 2017 Sep 26;9(3):7094. doi: 10.4081/hr.2017.7094. eCollection 2017 Sep 26. No abstract available.

15.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N.

Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.

16.

Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity.

Drabe M, Rullmann M, Luthardt J, Boettcher Y, Regenthal R, Ploetz T, Becker GA, Patt M, Schinke C, Bergh FT, Zientek F, Hilbert A, Bresch A, Fenske W, Hankir MK, Sabri O, Hesse S.

Transl Psychiatry. 2017 Jul 4;7(7):e1167. doi: 10.1038/tp.2017.133.

17.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ.

Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. No abstract available.

18.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ.

Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. No abstract available.

19.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

20.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C.

Am J Hematol. 2017 Aug;92(8):739-745. doi: 10.1002/ajh.24756. Epub 2017 Jun 1.

21.

Antibacterial Compounds from Marine Bacteria, 2010-2015.

Schinke C, Martins T, Queiroz SCN, Melo IS, Reyes FGR.

J Nat Prod. 2017 Apr 28;80(4):1215-1228. doi: 10.1021/acs.jnatprod.6b00235. Epub 2017 Mar 31. Review.

PMID:
28362500
22.

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M.

J Bone Miner Res. 2017 Jun;32(6):1261-1266. doi: 10.1002/jbmr.3111. Epub 2017 Mar 27.

23.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA.

Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.

24.

Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity.

Schinke C, Hesse S, Stoppe M, Meyer K, Schmidt E, Orthgiess J, Bechmann L, Bresch A, Rullmann M, Luthardt J, Sabri O, Blüher M, Kratzsch J, Then Bergh F.

Psychoneuroendocrinology. 2017 Apr;78:39-47. doi: 10.1016/j.psyneuen.2017.01.004. Epub 2017 Jan 16.

PMID:
28167369
25.

Instrumentation-related uncertainty of reflectance and transmittance measurements with a two-channel spectrophotometer.

Peest C, Schinke C, Brendel R, Schmidt J, Bothe K.

Rev Sci Instrum. 2017 Jan;88(1):015105. doi: 10.1063/1.4973633.

PMID:
28147649
26.

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.

Clin Cancer Res. 2017 Apr 15;23(8):1981-1987. doi: 10.1158/1078-0432.CCR-16-0235. Epub 2016 Oct 3.

27.

Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma.

Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A.

Transpl Infect Dis. 2016 Dec;18(6):939-941. doi: 10.1111/tid.12619. Epub 2016 Nov 10.

PMID:
27696648
28.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Sep 16;6:e471. doi: 10.1038/bcj.2016.85. No abstract available.

29.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.

30.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64. Erratum in: Blood Cancer J. 2016 Sep 16;6:e471.

31.

CA-125 secreting IgG kappa multiple myeloma.

Boota M, Schinke C, Ledoux S, Alapat D, Khan R, Barlogie B.

Am J Hematol. 2016 Oct;91(10):E457-8. doi: 10.1002/ajh.24456. Epub 2016 Jul 14. No abstract available.

32.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

33.

A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma.

Mohan M, Gokden M, Gokden N, Schinke C.

Am J Case Rep. 2016 Mar 18;17:173-6.

34.

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F.

Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Epub 2016 Feb 17. Review.

PMID:
26888183
35.

Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [(11)C] DASB positron emission tomography study.

Hesse S, Rullmann M, Luthardt J, Winter K, Hankir MK, Becker GA, Zientek F, Reissig G, Regenthal R, Drabe M, Schinke C, Bresch A, Arelin K, Lobsien D, Patt M, Meyer PM, Fasshauer M, Fenske WK, Blüher M, Stumvoll M, Sabri O.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1096-104. doi: 10.1007/s00259-015-3243-y. Epub 2015 Nov 18.

PMID:
26577939
36.

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A.

Blood. 2015 May 14;125(20):3144-52. doi: 10.1182/blood-2015-01-621631. Epub 2015 Mar 25. Erratum in: Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura].

37.

Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.

Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A.

Leuk Lymphoma. 2014 Dec;55(12):2901-6. doi: 10.3109/10428194.2014.894186. Epub 2014 Mar 20.

PMID:
24650011
38.

Stem cell origin of myelodysplastic syndromes.

Elias HK, Schinke C, Bhattacharyya S, Will B, Verma A, Steidl U.

Oncogene. 2014 Oct 30;33(44):5139-50. doi: 10.1038/onc.2013.520. Epub 2013 Dec 16. Review.

PMID:
24336326
39.

Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A.

J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50. Review.

40.

Recovery of Extracellular Lipolytic Enzymes from Macrophomina phaseolina by Foam Fractionation with Air.

Schinke C, Germani JC.

Enzyme Res. 2013;2013:897420. doi: 10.1155/2013/897420. Epub 2013 May 13.

41.

Linked-in: design and efficacy of antibody drug conjugates in oncology.

Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK.

Oncotarget. 2013 Mar;4(3):397-412.

42.

Boron chemicals in diagnosis and therapeutics.

Das BC, Thapa P, Karki R, Schinke C, Das S, Kambhampati S, Banerjee SK, Van Veldhuizen P, Verma A, Weiss LM, Evans T.

Future Med Chem. 2013 Apr;5(6):653-76. doi: 10.4155/fmc.13.38. Review.

43.

Glutamine and alanine-induced differential expression of intracellular IL-6, IL-8, and TNF-α in LPS-stimulated monocytes in human whole-blood.

Raspé C, Czeslick E, Weimann A, Schinke C, Leimert A, Kellner P, Simm A, Bucher M, Sablotzki A.

Cytokine. 2013 Apr;62(1):52-7. doi: 10.1016/j.cyto.2013.02.020. Epub 2013 Mar 13.

PMID:
23498057
44.

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB.

J Immunol. 2013 Mar 15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13.

45.
46.

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.

Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A.

Blood. 2012 Sep 6;120(10):2076-86. doi: 10.1182/blood-2011-12-399683. Epub 2012 Jul 2.

47.

Experimental setup for camera-based measurements of electrically and optically stimulated luminescence of silicon solar cells and wafers.

Hinken D, Schinke C, Herlufsen S, Schmidt A, Bothe K, Brendel R.

Rev Sci Instrum. 2011 Mar;82(3):033706. doi: 10.1063/1.3541766.

PMID:
21456750
48.

Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.

Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A, Das B.

Leuk Lymphoma. 2010 Jun;51(6):1108-14. doi: 10.3109/10428191003786766.

49.

Aberrant DNA methylation in malignant melanoma.

Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A.

Melanoma Res. 2010 Aug;20(4):253-65. doi: 10.1097/CMR.0b013e328338a35a. Review.

Supplemental Content

Loading ...
Support Center